Skip to main content
Clinical Trials/NCT06021275
NCT06021275
Recruiting
Not Applicable

Microneedling With Regular Insulin Versus Microneedling Alone in Treatment of Atrophic Scars

Alexandria University1 site in 1 country40 target enrollmentStarted: October 1, 2023Last updated:
ConditionsScarsInsulin

Overview

Phase
Not Applicable
Status
Recruiting
Enrollment
40
Locations
1
Primary Endpoint
Change in Scar

Overview

Brief Summary

Recently, few studies have attempted to test the regenerative effects of human insulin application by microneedling on atrophic scars versus other topical preparations. However, the scars were limited etiologically to acne scars. In addition, a lack of inclusion of a control group instead of comparing topical preparations with insulin was also a limitation to these studies. A control group consisting of microneedling alone would have served as a better comparison in order to determine whether the effects of microneedling are augmented by topical protein-rich preparations.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Participant)

Eligibility Criteria

Ages
12 Years to 60 Years (Child, Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients aged 12 to 60 years
  • Atrophic scars (traumatic or surgical)
  • Completely healed scars

Exclusion Criteria

  • Patients with a tendency or history of hypertrophic or keloidal scars
  • Patients who received treatment for their scar in the past 3 months
  • Diabetic patients or those with a history of Dysglycemia
  • Pregnant, or lactating females
  • Patients with active infection at the site of scar
  • Patients currently receiving isotretinoin treatment or in the past month

Outcomes

Primary Outcomes

Change in Scar

Time Frame: 4 months

According the different scar assessment scores (e.g.POSAS score - The Patient and Observer Scar Assessment Scale score, range from 6 to 60, the higher the score the worse the scar, lowering in the score denotes improvement )

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Dalia Ibrahim Halwag

Lecturer and Consultant of Dermatology, Venereology and Andrology, Faculty of Medicine

Alexandria University

Study Sites (1)

Loading locations...

Similar Trials